Here, we compared the ability of plasma and salivary antibodies from our vaccinated only and COVID-19–recovered cohorts to inhibit angiotensin-converting enzyme 2 (ACE2) binding to a series of RBDs, including ancestral SARS-CoV-2 and the various variants of concern (VoCs). This evidence concerns the gene ACE2 and COVID-19.